政府新闻

City News

生物制造枢纽上海启动   2023-12-10

 

A novel drug production base, with an annual capacity of 250 million tablets and 550 million capsules has been put into operation, becoming the first high-end biomanufacturing project in Shanghai's Zhangjiang innovative drug industry base, Chinese biopharmaceutical company HutchMed announced last Friday.

Taking up an area of 43 acres, the newly completed project in Shanghai's Zhangjiang Innovation Drug Industry Base is facilitating HutchMed's pursuit of building a first-class global manufacturing center and clinical sample preparation center in China. The company plans to supply local innovative products globally.

"Innovation is key to the biomedical industry development. More support will be granted to innovative pharmaceutical companies to strengthen their competitiveness and fulfill the city's goal of expanding its biomedical industry scale to trillion yuan in the years to come," said Li Jia, an official from the Shanghai Commission of Economy and Informatization.

"As a local innovative pharmaceutical company based in Shanghai's Pudong New Area for 21 years, HutchMed has benefited from the first-class business environment created by the governments at all levels in Shanghai," said Su Weiguo, chief executive officer and chief scientific officer of HutchMed.

Being one of the city's major strategic emerging industrial projects, construction of the HutchMed's innovative drug production base started three years ago.

Source: China Daily

 


注册记者登录

 

 

记者点此免费注册 | 忘记密码

采访申请流程

06月08日 21315203 受理中
02月16日 21315167 已办结
01月26日 21315166 已办结

咨询申请流程

06月12日 02131545 已办结
05月12日 02131544 已办结
05月06日 02131541 已办结

查看全部 »

共性问题提示

Q: 问:如果想要迅速了解上海这座...
A: 答:请注册登陆本网站“今日上...
Q: 问:如果您想在上海进行采访,...
A: 答:(1) 请注册登陆本网站...
Q: 在哪里可以买到上海的地图?
A: 上海各大书店中均有出售,一些...